RWF_MK-3475-016

Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors

This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in three different patient populations. These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative colon cancer, and 3. patients with other MSI positive cancers.

Inclusion Criteria:
• Arm 1 only: Patients with MSI positive colorectal cancer; Arm 2 only: Patients with MSI negative colorectal cancer; Arm 3 only: Patients with MSI positive non-colorectal cancer
• Have measurable disease

Exclusion Criteria:
• Patients who have had chemotherapy or biological cancer therapy within 2 weeks prior to the first dose of study drug
• Patients who have had radiation within 2 weeks prior to the first dose of study drug
• Systemically active steroid use

Phase II
NCT01876511
Oncology
Gastrointestinal
Todd Crocenzi, M.D.
Johns Hopkins University
Melissa Pomeroy
  • Oncology and Hematology Care Eastside